FDA

Plus Therapeutics shares rallied on Tuesday after an FDA update on its treatment of patients with recurrent glioblastoma.
The FDA has come down on an investigational treatment for moderately to severely active from Gilead Sciences and Galapagos.
BioMarin Pharmaceutical stock was crushed on Wednesday after an FDA response regarding its valoctocogene roxaparvovec gene therapy for severe hemophilia A.
Taiwan Liposome Co. Ltd (NASDAQ: TLC) shares shot higher on Friday after the company announced it was making a regulatory filing for a COVID-19 treatment that has been at the center of some...
The world may be focused on COVID-19 this year, but the battle against Alzheimer’s disease continues with no effective treatments. Biogen hopes to remedy that unfortunate situation.
Denali Therapeutics announced early Thursday that it would be progressing its Parkinson’s treatment into late-stage studies in collaboration with Biogen.
GW Pharmaceuticals shares popped early on Monday morning after the company announced that it received a key approval from the FDA for Epidiolex to treat certain seizures.
Johnson & Johnson has announced that it will launch its human study for its lead vaccine candidate in the United States and Belgium.
Edesa Biotech joins the list of COVID-19 stocks, as the company is making headway with regulatory agencies for its late-stage study. Investors were quick to give this firm the coronavirus bump, more...
Spectrum Pharmaceuticals announced good news for lung cancer patients in its midstage trial on Tuesday.
Pfizer and BioNTech made another big step in their fight against COVID-19 by initiating their late-stage study for their lead mRNA vaccine candidate.
Goldman Sachs has seven biopharma stocks on its Conviction Buy list, and these are not all coronavirus plays. The firm thinks these stocks could go on the offensive for the rest of the year.
Milestone Pharmaceuticals shares more than doubled on Thursday after the company announced a key clinical and regulatory update.
Pfizer and BioNTech S.E. aim to begin delivering 300 million doses of their vaccine for COVID-19 in 2021, but in the meantime, these companies will get a nice payoff.
Moleculin Biotech joins the ever-expanding list of coronavirus stocks as the company announced that a second round of independent laboratory testing has confirmed the antiviral activity of WP1122.